(NASDAQ: VALN) Valneva Se's forecast annual revenue growth rate of 24.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Valneva Se's revenue in 2026 is $200,757,471.On average, 8 Wall Street analysts forecast VALN's revenue for 2026 to be $31,523,494,679, with the lowest VALN revenue forecast at $27,636,204,391, and the highest VALN revenue forecast at $34,074,528,931. On average, 8 Wall Street analysts forecast VALN's revenue for 2027 to be $60,537,604,646, with the lowest VALN revenue forecast at $51,123,073,480, and the highest VALN revenue forecast at $75,073,293,687.
In 2028, VALN is forecast to generate $58,774,440,837 in revenue, with the lowest revenue forecast at $39,804,811,311 and the highest revenue forecast at $82,471,293,016.